Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer
AssigneeUniversitätsklinikum Regensburg
InventorsEdward Geissler, Maria Mycielska, Petra Rümmele
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method for the diagnosis of cancer involving the plasma membrane citrate transporter (pmCiC). The invention is further directed to a modified substrate or modulator of pmCiC, the use of pmCiC as a tumor marker and a method of screening for a modulator of pmCiC activity.
Claims2
A method of treating cancer in a patient in need thereof, the method comprising administering to the patient an inhibitor of plasma membrane citrate transporter (pmCiC) activity, wherein said cancer is selected from the group consisting of prostate cancer, gastric cancer, pancreatic cancer, breast cancer, and colon cancer and wherein said inhibitor of pmCiC activity is gluconate.
Dependencies are inferred from the claim text.